<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569202</url>
  </required_header>
  <id_info>
    <org_study_id>5503762</org_study_id>
    <nct_id>NCT03569202</nct_id>
  </id_info>
  <brief_title>Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye</brief_title>
  <official_title>A Randomized, Active-controlled, Parallel, Double-blind Study on the Safety, Ocular Tolerability and Efficacy of Piiloset Trehalose Emulsion Eye Drop in Adult Patients With Moderate or Severe Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnsusp Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>4Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Business Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the safety, ocular tolerability and efficacy of emulsion eye drops with
      sacha inchi seed oil, trehalose and hyaluronic acid in the treatment of moderate or severe
      dry eye in adult patients. The investigative device is studied in comparison with control eye
      drops containing hyaluronic acid for up to 30 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the current view on dry eye disease, tear film instability, tear film
      hyperosmolarity, and ocular surface inflammation and damage are identified as etiological
      factors. The first-line medicinal management options include ocular lubricants such as eye
      drops and sprays. Emulsion eye drops are a relatively recent entity among topical therapies
      with an intention to account for deficiencies in the outermost lipid layer of the tear film.

      Piiloset Trehalose Emulsion Eye Drops was developed to target and restore the three main
      layers (mucin, aqueous, and lipid) of the tear film and to counteract the key etiological
      factors leading to dry eye. Hyaluronic acid and the oil component are intended to restore
      tear film instability, the hypo-osmolar composition and trehalose as an osmoprotectant are
      intended to protect the ocular epithelium against hyperosmolarity, and ocular surface
      inflammation and cellular damage are prevented by the cytoprotective and/or anti-oxidative
      action of hyaluronic acid, trehalose, and sacha inchi oil components. Additional water
      binding in the tear film is provided by hyaluronic acid, trehalose, and glycerol. Lubricating
      the ocular surface by high-molecular-weight hyaluronic acid will extend the precorneal
      retention time. Adjustments made to certain physical and chemical parameters in the
      formulation are anticipated to improve tear film spreading and adhesion. The optically clear
      o/w emulsion formulation is free of preservatives, materials of animal origin, phosphates, or
      alcohol. The combined action of the individual components is expected to produce clinically
      relevant mitigation of the signs and symptoms of dry eye.

      The study comprises three Parts with scheduled visits on Day 1 (all Parts) and on
      end-of-study date (Parts 2 and 3) to the study centre. Each study subject will participate in
      no more than one Part of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Actual">November 8, 2018</completion_date>
  <primary_completion_date type="Actual">November 8, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1. Piiloset Trehalose Emulsion Eye Drop is administered on the worst eye four times during office hours of one day at the study centre.
Part 2. Piiloset Trehalose Emulsion Eye Drop is self-administered on a randomized eye and the control eye drops on the contralateral eye three times a day for 10 days in a double-blinded fashion.
Part 3. Either Piiloset Trehalose Emulsion Eye Drop or the control eye drops are self-administered on both eyes three times a day for 30 days in a randomized and double-blinded fashion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline OSDI</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Ocular Surface Disease Index (OSDI) is a questionnaire consisting of 12 questions subdivided into 3 subscales for measuring the frequency of dry eye symptoms, vision-related quality of life and environmental triggers during the previous week. Answers to each question are on a scale of 0 (None of the time) to 4 (All of the time). Both total OSDI and its subscale scores are on a scale of 0 to 100, calculated as follows: score = (sum of scores for questions answered/number of questions answered) x 25. Higher scores represent greater disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Tear Osmolarity</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Instrumental assay of tear fluid osmolarity (mOsm/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline TBUT</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Tear film break-up time (TBUT) (s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Blink Rate</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Measurement of spontaneous eyelid blinks per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Ocular Protection Index (OPI)</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>OPI is the ratio of TBUT/IBI (IBI, interblink interval calculated from blink rate). An OPI value &gt;1 indicates that TBUT (s) exceeds IBI (s) and that the ocular surface is mostly tear-film protected, because tear film break-ups do not take place within spontaneous blink cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Corneal Staining</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Corneal staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Conjunctival (Temporal) Staining</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Conjunctival staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Conjunctival (Nasal) Staining</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Conjunctival staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline Visual Acuity</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Best corrected visual acuity (ETDRS charts 1 &amp; 2, 2000 series)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline Conjunctival Redness</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Conjunctival redness score is assessed on an ordinal scale of 0 to 4 (IER grading scale):
0 = not existing, 1 = very slight, 2 = slight, 3 = moderate, 4 = severe. Higher score represents more intense redness.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline Lid Redness</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Eyelid redness score is assessed on an ordinal scale of 0 to 4 (IER grading scale):
0 = not existing, 1 = very slight, 2 = slight, 3 = moderate, 4 = severe. Higher score represents more intense redness.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline Intraocular Pressure</measure>
    <time_frame>From baseline to Day 30 (Part 3)</time_frame>
    <description>Intraocular pressure measured using Goldmann applanation tonometry (mmHg)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Emulsion Eye Drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Eye Drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Piiloset Trehalose Emulsion Eye Drops</intervention_name>
    <description>Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily</description>
    <arm_group_label>Emulsion Eye Drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Eye Drops</intervention_name>
    <description>Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily</description>
    <arm_group_label>Control Eye Drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability and willingness to give informed written consent prior to any screening
             procedure after explanation of the nature and possible consequences of the study.

          2. Age between 18 and 80 years.

          3. At least two the following conditions (A and B):

             A. Symptomatic dry eye with OSDI score ≥20. AND B1. Tear film break-up time (TBUT) &lt;10
             seconds. OR B2. Positive ocular (corneal and conjunctival) staining pattern

          4. Body weight at least 45 kg.

          5. Under stable topical and/or systemic therapy for at least 4 weeks before the study
             procedures and apparent ability and willingness to abstain from other therapies until
             completion of the study period.

          6. Ability and willingness to self-administer eye drops.

          7. Ability and willingness to understand and fill in the OSDI questionnaire.

          8. Ability and willingness to comply with the study protocol and other study-related
             procedures.

        Exclusion Criteria:

          1. History of ocular surgery, trauma, or refractive laser vision correction procedure
             less than 3 months earlier.

          2. Evidence of acute or chronic infection in the cornea or conjunctiva.

          3. Diagnosis of Sjögren's syndrome.

          4. Unwillingness or apparent disability to discontinue contact lens use during study
             period and at least one week before the first dosing day.

          5. Current ocular allergy symptoms.

          6. Known allergy to any constituent of the trehalose emulsion eye drops or control eye
             drops.

          7. Currently pregnant, nursing or planning to become pregnant before completion of the
             study period.

          8. Any other condition that may, in the Investigator's opinion, jeopardize the safety or
             availability of the subject or adherence to the study protocol or may interfere with
             the interpretation of the results and would thus make the subject inappropriate for
             entry in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Kaarniranta, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kuopio University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>FI-70200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1111/aos.14252</url>
    <description>Open access article</description>
  </link>
  <results_reference>
    <citation>Laihia J, Järvinen R, Wylęgała E, Kaarniranta K. Disease aetiology-based design of multifunctional microemulsion eye drops for moderate or severe dry eye: a randomized, quadruple-masked and active-controlled clinical trial. Acta Ophthalmol. 2020 May;98(3):244-254. doi: 10.1111/aos.14252. Epub 2019 Oct 3.</citation>
    <PMID>31579987</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <results_first_submitted>October 11, 2019</results_first_submitted>
  <results_first_submitted_qc>November 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2019</results_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kuopio University Hospital</investigator_affiliation>
    <investigator_full_name>Kai Kaarniranta</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>Lubricant Eye Drops</keyword>
  <keyword>Moderate or Severe Dry Eye</keyword>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Trehalose</keyword>
  <keyword>Disaccharides</keyword>
  <keyword>Polysaccharides</keyword>
  <keyword>Fatty Acids, Omega-3</keyword>
  <keyword>Tears</keyword>
  <keyword>Osmolar Concentration</keyword>
  <keyword>Anterior Eye Segment</keyword>
  <keyword>Severity of Illness Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03569202/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03569202/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study comprised three sequential parts. Parts 1 to 3 involved different participants each, thus no participant flow between parts (or periods) took place.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Emulsion Eye Drops</title>
          <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Piiloset Trehalose Emulsion Eye Drops: Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops
Part 1: on one eye 4 times during one day
Part 2: on one randomized eye 3 times a day for 10 days
Part 3: on both eyes 3 times a day for 30 days</description>
        </group>
        <group group_id="P2">
          <title>Control Eye Drops</title>
          <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Control Eye Drops: Topical application of preservative-free multidose Hyaluronic Acid Eye Drops
Part 1: not used
Part 2: on randomized contralateral eye 3 times a day for 10 days
Part 3: on both eyes 3 times a day for 30 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">Emulsion Eye Drops were used on one eye only.</participants>
                <participants group_id="P2" count="0">Control Eye Drops were not used for Part 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3">No participant completing Part 1 was allowed to continue to Parts 2 or 3.</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">Emulsion Eye Drops were used on one randomized eye. Participants were different from Part 1.</participants>
                <participants group_id="P2" count="9">Control Eye Drops were used on contralateral eye. Participants were different from Part 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">No participant completing Part 2 was allowed to continue to Part 3.</participants>
                <participants group_id="P2" count="9">No participant completing Part 2 was allowed to continue to Part 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">Emulsion Eye Drops were used on both eyes. Participants were different from Parts 1 and 2.</participants>
                <participants group_id="P2" count="26">Control Eye Drops were used on both eyes. Participants were different from Parts 1 and 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24">Per-protocol (PP) dataset. 'Not Completed' participants are included in safety and ITT datasets.</participants>
                <participants group_id="P2" count="25">Per-protocol (PP) dataset. 'Not Completed' participants are included in safety and ITT datasets.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Part 3: 52 eyes of 26 pts treated with Emulsion Eye Drops and 52 eyes of 26 pts treated with Control Eye Drops.
Results are reported for Part 3 only.</population>
      <group_list>
        <group group_id="B1">
          <title>Emulsion Eye Drops</title>
          <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
        </group>
        <group group_id="B2">
          <title>Control Eye Drops</title>
          <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="13.8"/>
                    <measurement group_id="B2" value="51.5" spread="11.4"/>
                    <measurement group_id="B3" value="53.3" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.1" spread="11.7"/>
                    <measurement group_id="B2" value="76.9" spread="15.8"/>
                    <measurement group_id="B3" value="76.0" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ocular Surface Disease Index (OSDI)</title>
          <description>Ocular Surface Disease Index (OSDI) is a questionnaire consisting of 12 questions subdivided into 3 subscales for measuring the frequency of dry eye symptoms, vision-related quality of life and environmental triggers during the previous week. Answers to each question are on a scale of 0 (None of the time) to 4 (All of the time). Both total OSDI and its subscale scores are on a scale of 0 to 100, calculated as follows: score = (sum of scores for questions answered/number of questions answered) x 25. Higher scores represent greater disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="10.8"/>
                    <measurement group_id="B2" value="45.6" spread="11.3"/>
                    <measurement group_id="B3" value="46.9" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tear Break-Up Time (TBUT)</title>
          <units>s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.35" spread="2.62"/>
                    <measurement group_id="B2" value="3.46" spread="2.04"/>
                    <measurement group_id="B3" value="3.40" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tear osmolarity</title>
          <units>mOsm/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304.0" spread="11.8"/>
                    <measurement group_id="B2" value="307.3" spread="12.4"/>
                    <measurement group_id="B3" value="305.6" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blink rate</title>
          <description>Measurement of spontaneous eyelid blinks per minute</description>
          <units>Blinks/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.17" spread="11.49"/>
                    <measurement group_id="B2" value="22.27" spread="12.93"/>
                    <measurement group_id="B3" value="20.22" spread="12.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ocular protection index (OPI)</title>
          <description>Ocular protection index (OPI) is the ratio of TBUT/IBI (IBI, interblink interval calculated from blink rate). An OPI value &gt;1 indicates that TBUT (s) exceeds IBI (s) and that the ocular surface is mostly tear-film protected, because tear film break-ups do not take place within spontaneous blink cycles.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.98" spread="0.937"/>
                    <measurement group_id="B2" value="1.23" spread="1.188"/>
                    <measurement group_id="B3" value="1.11" spread="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corneal staining</title>
          <description>Corneal staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.37" spread="0.794"/>
                    <measurement group_id="B2" value="1.21" spread="0.603"/>
                    <measurement group_id="B3" value="1.29" spread="0.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conjunctival staining (temporal)</title>
          <description>Conjunctival staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.06" spread="0.432"/>
                    <measurement group_id="B2" value="1.06" spread="0.497"/>
                    <measurement group_id="B3" value="1.06" spread="0.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conjunctival staining (nasal)</title>
          <description>Conjunctival staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.23" spread="0.430"/>
                    <measurement group_id="B2" value="1.23" spread="0.406"/>
                    <measurement group_id="B3" value="1.23" spread="0.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conjunctival redness</title>
          <description>Conjunctival redness score is assessed on an ordinal scale of 0 to 4 (Institute for Eye Research (IER) grading scale):
0 = not existing, 1 = very slight, 2 = slight, 3 = moderate, 4 = severe. Higher score represents more intense redness.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.98" spread="0.685"/>
                    <measurement group_id="B2" value="1.94" spread="0.829"/>
                    <measurement group_id="B3" value="1.96" spread="0.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lid redness</title>
          <description>Eyelid redness score is assessed on an ordinal scale of 0 to 4 (Institute for Eye Research (IER) grading scale):
0 = not existing, 1 = very slight, 2 = slight, 3 = moderate, 4 = severe. Higher score represents more intense redness.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.29" spread="0.751"/>
                    <measurement group_id="B2" value="1.29" spread="0.724"/>
                    <measurement group_id="B3" value="1.29" spread="0.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure</title>
          <units>mmHg (Goldmann tonometer)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.92" spread="2.134"/>
                    <measurement group_id="B2" value="15.69" spread="2.558"/>
                    <measurement group_id="B3" value="15.31" spread="2.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ocular surgery, trauma, refractive laser vision correction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eye infection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Allergy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current or planned pregnancy and nursing</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline OSDI</title>
        <description>Ocular Surface Disease Index (OSDI) is a questionnaire consisting of 12 questions subdivided into 3 subscales for measuring the frequency of dry eye symptoms, vision-related quality of life and environmental triggers during the previous week. Answers to each question are on a scale of 0 (None of the time) to 4 (All of the time). Both total OSDI and its subscale scores are on a scale of 0 to 100, calculated as follows: score = (sum of scores for questions answered/number of questions answered) x 25. Higher scores represent greater disability.</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Intent-to-treat (ITT) dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OSDI</title>
          <description>Ocular Surface Disease Index (OSDI) is a questionnaire consisting of 12 questions subdivided into 3 subscales for measuring the frequency of dry eye symptoms, vision-related quality of life and environmental triggers during the previous week. Answers to each question are on a scale of 0 (None of the time) to 4 (All of the time). Both total OSDI and its subscale scores are on a scale of 0 to 100, calculated as follows: score = (sum of scores for questions answered/number of questions answered) x 25. Higher scores represent greater disability.</description>
          <population>Intent-to-treat (ITT) dataset</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.64" spread="16.186"/>
                    <measurement group_id="O2" value="-26.53" spread="14.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.662</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.8837</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7081</ci_lower_limit>
            <ci_upper_limit>10.4756</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-24.6445</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.7199</ci_lower_limit>
            <ci_upper_limit>-18.5692</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-26.5283</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.6036</ci_lower_limit>
            <ci_upper_limit>-20.4529</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Tear Osmolarity</title>
        <description>Instrumental assay of tear fluid osmolarity (mOsm/L)</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Intent-to-treat (ITT) dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Tear Osmolarity</title>
          <description>Instrumental assay of tear fluid osmolarity (mOsm/L)</description>
          <population>Intent-to-treat (ITT) dataset</population>
          <units>mOsm/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.75" spread="16.224"/>
                    <measurement group_id="O2" value="-1.77" spread="21.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.575</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.9808</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.6005</ci_lower_limit>
            <ci_upper_limit>7.6390</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2098</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.7500</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.2593</ci_lower_limit>
            <ci_upper_limit>2.7593</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6381</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.7692</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2785</ci_lower_limit>
            <ci_upper_limit>5.7401</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline TBUT</title>
        <description>Tear film break-up time (TBUT) (s)</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Intent-to-treat (ITT) dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline TBUT</title>
          <description>Tear film break-up time (TBUT) (s)</description>
          <population>Intent-to-treat (ITT) dataset</population>
          <units>s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="3.424"/>
                    <measurement group_id="O2" value="0.87" spread="1.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.8462</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6792</ci_lower_limit>
            <ci_upper_limit>2.3715</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.7115</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6330</ci_lower_limit>
            <ci_upper_limit>2.7901</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1134</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.8654</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2132</ci_lower_limit>
            <ci_upper_limit>1.9440</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Blink Rate</title>
        <description>Measurement of spontaneous eyelid blinks per minute</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Intent-to-treat (ITT) dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Blink Rate</title>
          <description>Measurement of spontaneous eyelid blinks per minute</description>
          <population>Intent-to-treat (ITT) dataset</population>
          <units>Blinks/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="8.721"/>
                    <measurement group_id="O2" value="-2.15" spread="10.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.412</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.1731</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1016</ci_lower_limit>
            <ci_upper_limit>7.4477</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9918</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01923</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7105</ci_lower_limit>
            <ci_upper_limit>3.7490</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2516</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.1538</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8836</ci_lower_limit>
            <ci_upper_limit>1.5759</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Ocular Protection Index (OPI)</title>
        <description>OPI is the ratio of TBUT/IBI (IBI, interblink interval calculated from blink rate). An OPI value &gt;1 indicates that TBUT (s) exceeds IBI (s) and that the ocular surface is mostly tear-film protected, because tear film break-ups do not take place within spontaneous blink cycles.</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Intent-to-treat (ITT) dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Ocular Protection Index (OPI)</title>
          <description>OPI is the ratio of TBUT/IBI (IBI, interblink interval calculated from blink rate). An OPI value &gt;1 indicates that TBUT (s) exceeds IBI (s) and that the ocular surface is mostly tear-film protected, because tear film break-ups do not take place within spontaneous blink cycles.</description>
          <population>Intent-to-treat (ITT) dataset</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.078"/>
                    <measurement group_id="O2" value="0.05" spread="0.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5093</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007267</ci_lower_limit>
            <ci_upper_limit>1.0113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5596</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2046</ci_lower_limit>
            <ci_upper_limit>0.9146</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7770</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3047</ci_lower_limit>
            <ci_upper_limit>0.4053</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Corneal Staining</title>
        <description>Corneal staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Per-protocol (PP) dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Corneal Staining</title>
          <description>Corneal staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
          <population>Per-protocol (PP) dataset</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.695"/>
                    <measurement group_id="O2" value="-0.22" spread="0.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.447</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <param_type>Wilcoxon Z statistic</param_type>
            <param_value>-0.7604</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Conjunctival (Temporal) Staining</title>
        <description>Conjunctival staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Per-protocol (PP) dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Conjunctival (Temporal) Staining</title>
          <description>Conjunctival staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
          <population>Per-protocol (PP) dataset</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.507"/>
                    <measurement group_id="O2" value="-0.02" spread="0.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.522</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <param_type>Wilcoxon Z statistic</param_type>
            <param_value>-0.6396</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.119</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.900</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Conjunctival (Nasal) Staining</title>
        <description>Conjunctival staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Per-protocol (PP) dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Conjunctival (Nasal) Staining</title>
          <description>Conjunctival staining score is assessed as the average number of punctate dots on an ordinal scale of 0, 1, 2, 3, 4, and 5 (Oxford scale) when compared to a pictorial standard. The number of dots increases on a log scale. Higher score represents more intense staining.</description>
          <population>Per-protocol (PP) dataset</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.608"/>
                    <measurement group_id="O2" value="-0.12" spread="0.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.590</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <param_type>Wilcoxon Z statistic</param_type>
            <param_value>-0.5387</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.442</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline Visual Acuity</title>
        <description>Best corrected visual acuity (ETDRS charts 1 &amp; 2, 2000 series)</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Visual Acuity</title>
          <description>Best corrected visual acuity (ETDRS charts 1 &amp; 2, 2000 series)</description>
          <population>Safety dataset</population>
          <units>logMAR chart log units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.071"/>
                    <measurement group_id="O2" value="-0.04" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline Conjunctival Redness</title>
        <description>Conjunctival redness score is assessed on an ordinal scale of 0 to 4 (IER grading scale):
0 = not existing, 1 = very slight, 2 = slight, 3 = moderate, 4 = severe. Higher score represents more intense redness.</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Conjunctival Redness</title>
          <description>Conjunctival redness score is assessed on an ordinal scale of 0 to 4 (IER grading scale):
0 = not existing, 1 = very slight, 2 = slight, 3 = moderate, 4 = severe. Higher score represents more intense redness.</description>
          <population>Safety dataset</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.647"/>
                    <measurement group_id="O2" value="-0.27" spread="0.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.357</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <param_type>Wilcoxon Z statistic</param_type>
            <param_value>0.9208</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline Lid Redness</title>
        <description>Eyelid redness score is assessed on an ordinal scale of 0 to 4 (IER grading scale):
0 = not existing, 1 = very slight, 2 = slight, 3 = moderate, 4 = severe. Higher score represents more intense redness.</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Lid Redness</title>
          <description>Eyelid redness score is assessed on an ordinal scale of 0 to 4 (IER grading scale):
0 = not existing, 1 = very slight, 2 = slight, 3 = moderate, 4 = severe. Higher score represents more intense redness.</description>
          <population>Safety dataset</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.672"/>
                    <measurement group_id="O2" value="-0.19" spread="0.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.296</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <param_type>Wilcoxon Z statistic</param_type>
            <param_value>1.0440</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline Intraocular Pressure</title>
        <description>Intraocular pressure measured using Goldmann applanation tonometry (mmHg)</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Intraocular Pressure</title>
          <description>Intraocular pressure measured using Goldmann applanation tonometry (mmHg)</description>
          <population>Safety dataset</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="1.705"/>
                    <measurement group_id="O2" value="-0.42" spread="1.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline Tear Osmolarity in Hyperosmolar Participants</title>
        <description>Instrumental assay of tear fluid osmolarity (mOsm/L) in a hyperosmolar subgroup of participants (mean of eyes ≥308 mOsm/L)</description>
        <time_frame>From baseline to Day 30 (Part 3)</time_frame>
        <population>ITT population with hyperosmolar tears (mean of eyes ≥308 mOsm/L)</population>
        <group_list>
          <group group_id="O1">
            <title>Emulsion Eye Drops</title>
            <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Results are reported for Part 3 only:
Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Control Eye Drops</title>
            <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Results are reported for Part 3 only:
Topical application of preservative-free multidose Hyaluronic Acid Eye Drops on both eyes 3 times a day for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Tear Osmolarity in Hyperosmolar Participants</title>
          <description>Instrumental assay of tear fluid osmolarity (mOsm/L) in a hyperosmolar subgroup of participants (mean of eyes ≥308 mOsm/L)</description>
          <population>ITT population with hyperosmolar tears (mean of eyes ≥308 mOsm/L)</population>
          <units>mOsm/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.06" spread="10.425"/>
                    <measurement group_id="O2" value="-15.07" spread="16.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group comparison, change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.764</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.9911</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.6117</ci_lower_limit>
            <ci_upper_limit>11.6295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.0625</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.9280</ci_lower_limit>
            <ci_upper_limit>-6.1970</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>A two-sided p-value less than 0.05 was considered statistically significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.0714</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.2850</ci_lower_limit>
            <ci_upper_limit>-6.8579</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1: 1 day; Part 2: 10 days; Part 3: 30 days</time_frame>
      <desc>ADE (adverse device effect); AE (adverse event); SADE (serious adverse device effect); SAE (serious adverse event); USADE (unanticipated serious adverse device effect)
Total Number of Participants at Risk (safety population); Emulsion Eye Drops: 3 + 9 + 26 = 38 participants; Control Eye Drops: 0 + 9 + 26 = 35 participants.
Adverse events were collected throughout the study during visits to study site, in study diaries, and from direct contacts to study personnel between visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Emulsion Eye Drops</title>
          <description>Daily treatment with Piiloset Trehalose Emulsion Eye Drops
Adverse events are reported for the safety population in all parts of the study, including all randomized subjects who received Piiloset Trehalose Emulsion Eye Drops at least once and from whom at least one safety measurement was obtained after randomization.</description>
        </group>
        <group group_id="E2">
          <title>Control Eye Drops</title>
          <description>Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
Adverse events are reported for the safety population in all parts of the study, including all randomized subjects who received Hyaluronic Acid Eye Drops at least once and from whom at least one safety measurement was obtained after randomization.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>EN ISO 14155:2011</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>AE (adverse event)</sub_title>
                <description>Small cutaneous papules all over the body, judged by the Investigator to be unrelated to study treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restrictions on the PI are that the sponsor can review results communications 30 days prior to planned date of public release. If public release of information in communications may jeopardize protecting sponsor's immaterial rights, the sponsor can additionally embargo the communications for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jarmo Laihia, Manager of Clinical &amp; Formulation Development</name_or_title>
      <organization>Finnsusp Ltd.</organization>
      <phone>358 50 377 1212</phone>
      <email>jarmo.laihia@piiloset.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

